Nicox announced that an affiliate of its licensee, Bausch + Lomb, has launched Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% in Mexico. Approval was obtained in Mexico in January 2020.
Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. First approved by the FDA in late 2017, Vyzulta is now commercialized in the United States, Canada, Argentina and Mexico. It is also approved in 4 other territories–Colombia, Hong Kong, Taiwan and Ukraine.
Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of Vyzulta plus up to $150 million in potential future milestones payments.
Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.